In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
What are Cancer Neoantigens? The Link Between Neoantigens and Immunotherapy – What's New in GU?
IJMS, Free Full-Text
JCI - Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression
Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer - ScienceDirect
Frontiers Neoantigen: A New Breakthrough in Tumor Immunotherapy
DCs can TAP out of ordinary cross-presentation
Neoantigens and their potential applications in tumor immunotherapy (Review)
Developing neoantigen-targeted T cell–based treatments for solid tumors
What Are Neoantigens?
Unleashing Our Immune Response to Quash Cancer
